Radiopharm Theranostics annual return on equity
2024
2025
Radiopharm Theranostics Return on Equity (ROE) Growth & History (RADX)
Radiopharm Theranostics's return on equity was −109.20% for fiscal 2025.
View full Radiopharm Theranostics company overviewRadiopharm Theranostics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | −109.20% | +22.29 pp |
| 2024 | 2024-06-30 | −131.49% | — |
Radiopharm Theranostics return on equity trends
Between the periods ended 2024-06-30 and 2025-06-30, Radiopharm Theranostics's return on equity increased from −131.49% to −109.20%, a change of +22.29 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Radiopharm Theranostics source filings ↗